Recent Updates
Recently added Catalysts
CYTK Negative Sentiment Score: 20/100

Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CYTK

Key Takeaway: Cytokinetics, Incorporated is facing a class action lawsuit filed by the DJS Law Group for alleged violations of securities laws. The suit claims that the company made false statements to investors regarding the expected FDA approval of aficamten and failed to submit necessary risk management documentation, which could hinder the approval process. Shareholders who purchased shares during the class period, December 27, 2023 to May 6, 2025, are encouraged to participate in the legal proceedings. The deadline for shareholders to act is November 17, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Cytokinetics is facing a class action lawsuit for securities law violations.
  • The lawsuit claims Cytokinetics made false and misleading statements regarding FDA approval for aficamten.
  • The failure to submit a Risk Evaluation and Mitigation Strategy (REMS) could delay the FDA approval process.
  • Public statements made by the company were deemed materially misleading throughout the class period.

Full Press Release Details

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 27, 2023 to May 6, 2025
DEADLINE: November 17, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Cytokinetics touted the expected FDA approval of aficamten to investors, stating that it expected approval in the second half of 2025. The Company failed to submit a Risk Evaluation and Mitigation Strategy (“REMS”), which could delay the FDA’s approval process. The Company later admitted it did not submit a REMS despite multiple pre-NDA meetings with the FDA on the subject of risk mitigation. Based on these facts, Cytokinetics’ public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against Cytokinetics about?

The lawsuit claims Cytokinetics made false statements regarding FDA approval for aficamten.

What is the deadline for joining the Cytokinetics lawsuit?

The deadline to join the class action is November 17, 2025.

What time frame does the class period cover?

The class period spans from December 27, 2023, to May 6, 2025.

Do I need to be a lead plaintiff to recover losses?

No, you do not need to be a lead plaintiff to participate in the recovery.

How will shareholders be updated during the case?

Shareholders will receive status updates via a portfolio monitoring software.

Last updated: Oct 27, 2025